Evaluation of the effectiveness of remdesivir in treating severe COVID-19 using data from the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, national cohort study
View ORCID ProfileBN Arch, View ORCID ProfileD Kovacs, View ORCID ProfileJT Scott, View ORCID ProfileAP Jones, View ORCID ProfileEM Harrison, View ORCID ProfileA Rosala-Hallas, View ORCID ProfileCG Gamble, View ORCID ProfilePJM Openshaw, View ORCID ProfileJK Baillie, View ORCID ProfileMG Semple on behalf of ISARIC4C Investigators
doi: https://doi.org/10.1101/2021.06.18.21259072
BN Arch
1Liverpool Clinical Trials Centre, Clinical Directorate, Faculty of Health and Life Sciences, University of Liverpool, UK
D Kovacs
2Institute of Biodiversity, Animal health and Comparative Medicine, University of Glasgow, Glasgow, UK
JT Scott
3MRC-University of Glasgow Centre for Virus Research, Glasgow, UK
AP Jones
1Liverpool Clinical Trials Centre, Clinical Directorate, Faculty of Health and Life Sciences, University of Liverpool, UK
EM Harrison
4Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK
A Rosala-Hallas
1Liverpool Clinical Trials Centre, Clinical Directorate, Faculty of Health and Life Sciences, University of Liverpool, UK
CG Gamble
1Liverpool Clinical Trials Centre, Clinical Directorate, Faculty of Health and Life Sciences, University of Liverpool, UK
PJM Openshaw
5National Heart and Lung Institute, Imperial College London, London, UK
JK Baillie
6Roslin Institute, University of Edinburgh, Edinburgh, UK
MG Semple
7Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK
8Department of Respiratory Medicine, Alder Hey Children’s Hospital, Liverpool, UK
Data Availability
This work uses data provided by patients and collected by the NHS as part of their care and support #DataSavesLives. ISARIC4C welcomes applications for data and material access through our Independent Data and Material Access Committee (https://isaric4c.net).
Posted June 21, 2021.
Evaluation of the effectiveness of remdesivir in treating severe COVID-19 using data from the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, national cohort study
BN Arch, D Kovacs, JT Scott, AP Jones, EM Harrison, A Rosala-Hallas, CG Gamble, PJM Openshaw, JK Baillie, MG Semple
medRxiv 2021.06.18.21259072; doi: https://doi.org/10.1101/2021.06.18.21259072
Evaluation of the effectiveness of remdesivir in treating severe COVID-19 using data from the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, national cohort study
BN Arch, D Kovacs, JT Scott, AP Jones, EM Harrison, A Rosala-Hallas, CG Gamble, PJM Openshaw, JK Baillie, MG Semple
medRxiv 2021.06.18.21259072; doi: https://doi.org/10.1101/2021.06.18.21259072
Subject Area
Subject Areas
- Addiction Medicine (317)
- Allergy and Immunology (621)
- Anesthesia (162)
- Cardiovascular Medicine (2318)
- Dermatology (205)
- Emergency Medicine (373)
- Epidemiology (11653)
- Forensic Medicine (10)
- Gastroenterology (688)
- Genetic and Genomic Medicine (3656)
- Geriatric Medicine (344)
- Health Economics (625)
- Health Informatics (2341)
- Health Policy (922)
- Hematology (337)
- HIV/AIDS (765)
- Medical Education (362)
- Medical Ethics (102)
- Nephrology (394)
- Neurology (3407)
- Nursing (193)
- Nutrition (512)
- Oncology (1788)
- Ophthalmology (529)
- Orthopedics (212)
- Otolaryngology (284)
- Pain Medicine (227)
- Palliative Medicine (66)
- Pathology (442)
- Pediatrics (1015)
- Primary Care Research (411)
- Public and Global Health (6047)
- Radiology and Imaging (1243)
- Respiratory Medicine (816)
- Rheumatology (373)
- Sports Medicine (319)
- Surgery (392)
- Toxicology (50)
- Transplantation (171)
- Urology (144)